Dna X (SONM) Net Equity Issued and Repurchased (2018 - 2025)

Dna X's Net Equity Issued and Repurchased history runs 7 years deep, the most recent figure standing at -$5.6 million for Q4 2025.

• Quarterly Net Equity Issued and Repurchased fell 2764.11% year-over-year to -$5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (down 50.21% YoY) and the FY2025 annual result came in at $8.2 million, up 105.37% from the prior year.
• Net Equity Issued and Repurchased was -$5.6 million for Q4 2025 at Dna X, down from $4.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $18.7 million in Q4 2021 and bottomed at -$5.6 million in Q4 2025.
• A 4-year average of $4.1 million and a median of $1.9 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased surged 62086.67% — and 2025, when it tumbled 2764.11%.
• Dna X's Net Equity Issued and Repurchased stood at $18.7 million in 2021, then tumbled by 99.99% to $1000.0 in 2022, then surged by 20800.0% to $209000.0 in 2024, then tumbled by 2764.11% to -$5.6 million in 2025.
• Business Quant data shows SONM's Net Equity Issued and Repurchased at -$5.6 million in Q4 2025, $4.8 million in Q3 2025, and $4.5 million in Q2 2025.